Clinical trial of PRCN 323 in children with adrenoleucodystrophy.

Trial Profile

Clinical trial of PRCN 323 in children with adrenoleucodystrophy.

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 May 2014

At a glance

  • Drugs PRCN 323 (Primary)
  • Indications Adrenoleucodystrophy
  • Focus Adverse reactions
  • Sponsors Neuralgene
  • Most Recent Events

    • 12 May 2014 New trial record
    • 29 Apr 2014 The first patient has been treated and this trial will be expanded to more patients, according to a Neuralgene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top